If you needed further reassurance that VC investor sentiment in biotech is starting to rebound, look no further than Forbion. The European life-sciences-focused growth fund cited “high demand” from investors after raising 1.35 billion euros ($1.5 billion) across two funds, marking the firm’s largest fundraising to date.
As the former global brand leader of Merck’s antifungal business, Francesco Maria Lavino knows his facts: There are only three classes of antifungals.
Naarden, The Netherlands, 4 August 2022 – Forbion, a leading European life sciences venture capital firm, today announces the $70 million financing of F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections with a high unmet medical need.
Forbion appoints Dr. Peter Høngaard Andersen as Operating Partner and Dr. Matt Cooper as Venture Partner Naarden, The Netherlands – 20 July 2022 – Forbion, a leading European life sciences venture...
European venture capital firm Forbion announced Thursday morning an initial close of €470 million ($504 million) for its second growth fund meant to boost late clinical-stage biotechs.
LONDON, Feb. 23, 2022 /PRNewswire/ -- Complement Therapeutics Ltd (CTx), a preclinical stage University of Manchester spinout, announced today the completion of its EUR 5 million seed financing round from BioGeneration Ventures (BGV) and Forbion, two leading European venture capital firms. BGV provided the initial seed-funding in early 2021 with both Forbion and BGV now investing additional seed financing.
Armgo Pharma is returning to its roots to deliver clinical proof of concept for its pipeline-in-a-product. After shifting focus from abnormal heart rhythm to neuromuscular disorders, Armgo is now returning to arrhythmias for its push into phase 2—and has armed itself with $35 million from Forbion and other VCs to go after the indication.